George Ansstas
Washington University in St. Louis
71 Papers
85 Citations
George Ansstas is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 42 publications.
Chat about Author
Papers
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Mi Hae Lim,Michael Weller,Ahmed Idbaih,Joachim P. Steinbach,G. Finocchiaro,Raju R. Raval,George Ansstas,Joachim M. Baehring,Jennie Taylor,Jérôme Honnorat,Kevin Petrecca,Filip De Vos,Antje Wick,Ashley Love Sumrall,Solmaz Sahebjam,Ingo K. Mellinghoff,Masashi Kinoshita,Mustimbo Roberts,Ruta Slepetis,Deepti M. Warad,David Leung,Michelle Lee,David A. Reardon,Antonio Omuro +23 more
TL;DR: NIVO added to RT+TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter and no new safety signals were observed.
Immunogenomics of Hypermutated Glioblastoma: a Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns,Christopher A. Miller,Ian G. Dorward,Christina Tsien,Edward F. Chang,Arie Perry,Ravindra Uppaluri,Cole J. Ferguson,Robert E. Schmidt,Sonika Dahiya,George Ansstas,Elaine R. Mardis,Gavin P. Dunn +12 more
TL;DR: It is provided proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Ansstas,Charles Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudhary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Lynne P. Taylor,Julian K. Wu,Erin M. Dunbar,Arnold B. Etame,Santosh Kesari,David Mathieu,David Piccioni,David S. Baskin,Michel Lacroix,Sven-Axel May,Pamela New,Timothy J. Pluard,Steven A. Toms,Victor Tse,Scott Peak,John L. Villano,James Battiste,Paul Mulholland,Michael Pearlman,Kevin Petrecca,Michael Schulder,Robert M. Prins,Alton L. Boynton,Marnix L. Bosch +72 more
TL;DR: In this article , treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) was associated with improved overall survival (OS) for patients with newly diagnosed glioblastoma (nGBM) and recurrent gliomatosis (rGBM), compared with standard of care (SOC).
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions.
TL;DR: Despite the limited success in development of effective therapeutics in glioblastoma, many treatment approaches hold potential promise including immunotherapy and novel combinational drugs.
57
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
Adnan Khattak,Jeffrey S. Weber,Tarek Meniawy,Matthew H. Taylor,George Ansstas,Kevin B. Kim,Meredith Ann McKean,Georgina V. Long,Ryan J. Sullivan,Mark B. Faries,Thuy Tran,C. Lance Cowey,Theresa Medina,Jennifer Segar,Victoria Atkinson,Geoffrey T. Gibney,Jason J. Luke,Elizabeth I. Buchbinder,Robert S. Meehan,G. Carlino +19 more
TL;DR: The mRNA-4157-P201/Keynote-942 trial as discussed by the authors showed a statistically significant and clinically meaningful improvement in RFS in the combination therapy compared to pembrolizumab monotherapy.
44